The Integrated Forecasting and Analysis Tool   Login Now

ADVENTRX Pharmaceuticals

EvaluatePharma® delivers unique insight into the past and future performance of companies in the pharmaceutical and biotechnology sector, in a user-friendly, online subscription service. A small selected sample of reports and related news headlines for ADVENTRX Pharmaceuticals are available below. Free sample reports are also available for other Companies. To find out how you can access more detailed information on ADVENTRX Pharmaceuticals, or on any other Company covered by EvaluatePharma® Contact Us today.

PIPELINE ANALYSIS - Sales Forecasts available to EvaluatePharma Subscribers

Rank Product Therapeutic Category Therapeutic Subcategory Pharmacological Class Phase (Current) ADVENTRX Pharmaceuticals - CoFactor Oncology & Immunomodulators Other anti-cancers 5-FU modulator Phase III   - Selone Oncology & Immunomodulators Alkylating agents Alkylating agent Pre-clinical   - ANX-201 Systemic Anti-infectives Anti-virals NNRTI Pre-clinical

FINANCIAL DATA ($US mln) - Forecasts available to EvaluatePharma Subscribers

ADVENTRX Pharmaceuticals   2005 2006  Valuation Measures   Based on Latest Share Prices      Valuing the Equity        Market Capitalisation 31 31        PE Ratio (diluted) - Normalised (x) (1.5) (1.4)        Valuing the Enterprise        Enterprise Value (3) (3)        Free Cash Flow (Pre-Dividends) (12) (16)        FCF Yield (%) 427.9% 574.2%    Forecast Financials   Income Statement      Total Revenues 0 0      S,G & A (5) (7)      R&D (9) (12)      Other Income/ Expense - Net 0 0      EBIT - Normalised (14) (19)      Net Interest & Financial Items 0 1      Pre-tax Profits - Normalised (13) (18)      Exceptionals - (10)      Income Before Taxes (13) (29)      Tax 0 0      Tax Rate (%) 0.0% 0.0%      Net Income - Reported (13) (29)      Net Income - Normalised (13) (18)     Per Share Data      EPS - Diluted (0.22) (0.39)      EPS - Basic (0.22) (0.39)      EPS - Normalised (diluted) (0.22) (0.25)      EPS - Normalised (basic) (0.22) (0.25)      Avg. Shares Outstanding - Diluted 59.8 74.0      Avg. Shares Outstanding - Basic 59.8 74.0      DPS 0.00 0.00

NEWS - Selected Product News Headlines (as of 11 June 2008)

ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)   (ADVENTRX Pharmaceuticals)   03-Jun-2008 ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study   (ADVENTRX Pharmaceuticals)   16-May-2008 ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study   (ADVENTRX Pharmaceuticals)   15-Apr-2008 ANX-201 Demonstrates a Unique Resistance Profile in Preclinical Tests   (ADVENTRX Pharmaceuticals)   31-Mar-2008 Complete ANX-530 Safety Data to be Published in the 2008 Proceedings of the American Society of Clinical Oncology   (ADVENTRX Pharmaceuticals)   10-Mar-2008 ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting   (ADVENTRX Pharmaceuticals)   07-Feb-2008 ADVENTRX Announces ANX-530 Safety Data and Provides NDA Submission Guidance   (ADVENTRX Pharmaceuticals)   14-Jan-2008 ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer   (ADVENTRX Pharmaceuticals)   05-Dec-2007 ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study   (ADVENTRX Pharmaceuticals)   16-Nov-2007 ADVENTRX Provides Update on Cofactor(R) Program   (ADVENTRX Pharmaceuticals)   02-Nov-2007 ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests   (ADVENTRX Pharmaceuticals)   25-Oct-2007 ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study   (ADVENTRX Pharmaceuticals)   10-Oct-2007 ADVENTRX Appoints Vice President of Commercialization   (ADVENTRX Pharmaceuticals)   08-Oct-2007 ADVENTRX Pharmaceuticals to Report Results from Phase 2b Clinical Trial of ANX-510 (Cofactor(R))   (ADVENTRX Pharmaceuticals)   01-Oct-2007 ADVENTRX Pharmaceuticals Announces Results From Phase 2b Clinical Trial of ANX-510 (CoFactor(R))   (ADVENTRX Pharmaceuticals)   01-Oct-2007 ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA   (ADVENTRX Pharmaceuticals)   10-Sep-2007 ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer   (ADVENTRX Pharmaceuticals)   16-Aug-2007 ANX-201 Combination Therapy Demonstrates Synergistic Inhibition of HIV-1 in Preclinical Tests   (ADVENTRX Pharmaceuticals)   23-Jul-2007

IN-DEPTH COMPETITIVE INTELLIGENCE AVAILABLE ON

Product Generic Name ADVENTRX Pharmaceuticals ANX-015 clarithromycin   ANX-016 vancomycin   ANX-201 -   ANX-513 paclitaxel   ANX-514 docetaxel   ANX-530 vinorelbine tartrate   ANX-570 beta-elemene   ANX-575 alpha-tocopheryl succinate   BlockAide/CR -   BlockAide/VP -   CoFactor folitixorin   EradicAide HIV vaccine   Selone -   Zanaflu chitosan & zinc

EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts for marketed and emerging products are built-up using recent research reports from top equity analysts. Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I, phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy, patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates, deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age - plus many more data items and analytics unique to EvaluatePharma®. Aggregations of these measures at a high-level means that companies may be ranked against each other on items such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs organic sales), sales by therapy area or technology and various other concentration measures. These aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis. Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.

Source: EvaluatePharma ®

Generated at 13:52:39 (GMT) on 11-Jun-2008

© 2008 EvaluatePharma Ltd